EX-99.1
2
exh99-1.txt
PRESS RELEASE DATED DECEMBER 28, 2005
EXHIBIT 99.1
NEWS from Carrington
FOR IMMEDIATE RELEASE
For Information Contact:
Carlton E. Turner, Chief Executive Officer
(972) 518-1300
CARRINGTON COMPLETES SALE-LEASEBACK TRANSACTION
IRVING, TEXAS - December 28, 2005 - Carrington Laboratories, Inc. (Nasdaq:
CARN) today announced that it has successfully completed the sale-leaseback
of its Irving, Texas headquarters facility. The transaction was finalized
on December 23, 2005 for $4.8 million.
Carrington has agreed to lease the building for a period of 15 years,
subject to further renewal options and certain defined rights of first
refusal and repurchase. The lease is a triple-net lease with rent
escalations after the fifth and tenth years.
The sale agreement, originally entered into on October 20, 2005 with Ranier
Capital Management, L.P. was assigned by Ranier, in accordance with its
rights in the agreement, to two investor trusts based in California.
Carrington received net proceeds of approximately $4.1 million from the
sale, which are expected to be used for general corporate purposes.
Magellan Commercial Realty, Inc. represented Carrington in the transaction.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,
biopharmaceutical and consumer products company currently utilizing
naturally-occurring complex carbohydrates to manufacture and market products
for mucositis, radiation dermatitis, wound and oral care, as well as to
manufacture and market the nutraceutical raw material Manapol[R] and
cosmetic raw material Hydrapol[TM]. Carrington also manufactures and markets
consumer products and manufactures quality products for other companies.
Manufacturing operations comply with cGMP standards. Carrington's DelSite
Biotechnologies subsidiary is developing its proprietary GelSite[R]
technology designed to provide controlled release of peptide and protein-
based drugs. Carrington's technology is protected by more than 130
patents in 26 countries. Select products carry the CE mark, recognized by
more than 20 countries around the world. For more information, visit
www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be
forward-looking. Actual events will be dependent upon a number of
factors and risks including, but not limited to: subsequent
changes in plans by the Company's management; delays or problems
in formulation, manufacturing, distribution, production and/or
launch of new finished products; changes in the regulatory
process; changes in market trends; and a number of other factors
and risks described from time to time in the Company's filings
with the Securities & Exchange Commission, including the Form
10-Q, filed November 14, 2005.
- stop -

EX - 99 . 1 2 exh99 - 1 . txt PRESS RELEASE DATED DECEMBER 28 , 2005 EXHIBIT 99 . 1 NEWS from Carrington FOR IMMEDIATE RELEASE For Information Contact : Carlton E. Turner , Chief Executive Officer ( 972 ) 518 - 1300 CARRINGTON COMPLETES SALE - LEASEBACK TRANSACTION IRVING , TEXAS - December 28 , 2005 - Carrington Laboratories , Inc . ( Nasdaq : CARN ) today announced that it has successfully completed the sale - leaseback of its Irving , Texas headquarters facility . The transaction was finalized on December 23 , 2005 for $ 4.8 million . Carrington has agreed to lease the building for a period of 15 years , subject to further renewal options and certain defined rights of first refusal and repurchase . The lease is a triple - net lease with rent escalations after the fifth and tenth years . The sale agreement , originally entered into on October 20 , 2005 with Ranier Capital Management , L . P . was assigned by Ranier , in accordance with its rights in the agreement , to two investor trusts based in California . Carrington received net proceeds of approximately $ 4.1 million from the sale , which are expected to be used for general corporate purposes . Magellan Commercial Realty , Inc . represented Carrington in the transaction . About Carrington Carrington Laboratories , Inc . is an ISO 9001 - certified , research - based , biopharmaceutical and consumer products company currently utilizing naturally - occurring complex carbohydrates to manufacture and market products for mucositis , radiation dermatitis , wound and oral care , as well as to manufacture and market the nutraceutical raw material Manapol [ R ] and cosmetic raw material Hydrapol [ TM ] . Carrington also manufactures and markets consumer products and manufactures quality products for other companies . Manufacturing operations comply with cGMP standards . Carrington 's DelSite Biotechnologies subsidiary is developing its proprietary GelSite [ R ] technology designed to provide controlled release of peptide and protein - based drugs . Carrington 's technology is protected by more than 130 patents in 26 countries . Select products carry the CE mark , recognized by more than 20 countries around the world . For more information , visit www.carringtonlabs.com . Certain statements in this release concerning Carrington may be forward - looking . Actual events will be dependent upon a number of factors and risks including , but not limited to : subsequent changes in plans by the Company 's management ; delays or problems in formulation , manufacturing , distribution , production and / or launch of new finished products ; changes in the regulatory process ; changes in market trends ; and a number of other factors and risks described from time to time in the Company 's filings with the Securities & Exchange Commission , including the Form 10 - Q , filed November 14 , 2005 . - stop -
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O